T A Syed

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream
    T A Syed
    Department of Dermatology, University of California, San Francisco, USA
    Trop Med Int Health 4:284-7. 1999
  2. ncbi Butenafine hydrochloride: for the treatment of interdigital tinea pedis
    T A Syed
    Department of Dermatology, University of California San Francisco, Box 0989, 90 Medical Center Way, Surge Building 110, San Francisco, CA 94143 0989, USA
    Expert Opin Pharmacother 1:467-73. 2000
  3. ncbi Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study
    T A Syed
    Department of Clinical Physiology, Malmo University Hospital, University of Lund, Sweden
    Int J STD AIDS 9:769-72. 1998
  4. ncbi Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: a placebo-controlled double-blind study
    T A Syed
    Department of Dermatology, University of California San Francisco 94143 0989, USA
    Int J STD AIDS 11:371-4. 2000
  5. ncbi Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study
    T A Syed
    Department of Dermatology, University of California San Francisco, 90 Medical Center Way, San Francisco, CA 94143 0989, USA
    J Cutan Med Surg 5:299-302. 2001
  6. ncbi A review of the applications of imiquimod: a novel immune response modifier
    T A Syed
    Department of Dermatology, University of California San Francisco, 94143 0989, USA
    Expert Opin Pharmacother 2:877-82. 2001

Detail Information

Publications6

  1. ncbi Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream
    T A Syed
    Department of Dermatology, University of California, San Francisco, USA
    Trop Med Int Health 4:284-7. 1999
    ..During follow-up, no relapse occurred in cured patients and no improvement was seen in medication-resistant and placebo participants...
  2. ncbi Butenafine hydrochloride: for the treatment of interdigital tinea pedis
    T A Syed
    Department of Dermatology, University of California San Francisco, Box 0989, 90 Medical Center Way, Surge Building 110, San Francisco, CA 94143 0989, USA
    Expert Opin Pharmacother 1:467-73. 2000
    ..If incorporated properly in semisolid topical preparations, with a balanced vehicle, butenafine hydrochloride potentially exhibits as a promising alternative antimycotic agent for the treatment of tinea pedis...
  3. ncbi Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study
    T A Syed
    Department of Clinical Physiology, Malmo University Hospital, University of Lund, Sweden
    Int J STD AIDS 9:769-72. 1998
    ..In conclusion, the findings showed that along with non-objective mild side effects, human leukocyte interferon-alpha (2 x 10(6) IU/g) in a hydrophilic gel is significantly more effective than placebo to cure intravaginal warts in women...
  4. ncbi Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: a placebo-controlled double-blind study
    T A Syed
    Department of Dermatology, University of California San Francisco 94143 0989, USA
    Int J STD AIDS 11:371-4. 2000
    ..In conclusion, the clinical results of the study demonstrate that 5-fluorouracil (1%) in a vaginal hydrophilic gel is safe, tolerable and significantly more effective than placebo to cure intravaginal warts in women...
  5. ncbi Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study
    T A Syed
    Department of Dermatology, University of California San Francisco, 90 Medical Center Way, San Francisco, CA 94143 0989, USA
    J Cutan Med Surg 5:299-302. 2001
    ..Methotrexate has been used as one of the first and systemic therapies for psoriasis. In general, 70% of patients with psoriasis prefer topical therapy as the treatment of choice...
  6. ncbi A review of the applications of imiquimod: a novel immune response modifier
    T A Syed
    Department of Dermatology, University of California San Francisco, 94143 0989, USA
    Expert Opin Pharmacother 2:877-82. 2001
    ..As a potent immune response modifier and an agent stimulating cell-mediated immune responses, imiquimod appears to be a promising drug to treat many skin disorders, infections and neoplasms...